AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%
VANCOUVER, British Columbia--(BUSINESS WIRE)--AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 2800 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 2800 mg (LY-CoV16) together significantly reduced COVID-19 related hospitalizations and deaths (collectively, ?events?) in more than 1,000 high-risk patients recently diagnosed with COVID-19.
Key details from the randomized, double-blind, placebo-controlled BLAZE-1 Phase 2/3 study are as follows:
- The trial met its primary endpoint and key secondary endpoints with high statistical significance;
- Bamlanivimab and etesevimab together reduced COVID-19 events by 70% versus placebo (p=0.0004); and
- All deaths occurred in patients taking the placebo. No deaths occurred in patients taking bamlanivimab and etesevimab together.